With unrestricted educational grant from

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "With unrestricted educational grant from"

Transcription

1 HOTEL MAKSOUD PLAZA SÃO PAULO SP BRASIL OCTOBER 22-23, 2009

2 Organization With unrestricted educational grant from

3 As the President of the Brazilian Society of Internal Medicine and the Brazilian Clinical Research Institute (BCRI) I am honored to welcome you to the 2 nd. International Symposium of Thrombosis and Anticoagulation ISTA The main purpose of this symposium is to discuss the most recent evidence on thrombosis and anticoagulation, including new agents under development and novel diagnostic tools in the field. The focus is to understand how to better apply the evidence into clinical practice so that the patients will gain and you will enhance the quality of care you offer your patients. This meeting provides a unique opportunity to witness the latest knowledge in this field. The clinical aspects including the most update treatments are our major objective in order to offer you concise answers that will help in the patient management on a day-by-day basis. I Hope you enjoy this scientific program and take advantage of the presence of our expert national and international faculty. Antonio Carlos Lopes, MD, PhD, FACP Brazilian Society of Internal Medicine President

4

5 Co-Chairs Becker, Richard C. MD Lopes, Renato D. MD, MHS, PhD Federal University of Sao Paulo (UNIFESP-EPM) International Faculty Alexander, John H. Garcia, David University of New Mexico (USA) Granger, Christopher B. Handller, Allison Jolicoeur, E. Marc Montreal Heart Institute (Canada) Newby, L. Kristin Pieper, Karen S. National Faculty Baruzzi, Antonio Claudio Carvalho, Antonio Carlos Chamone, Dalton de Alencar F. Guimarães, Hélio Penna Lopes, Antonio Carlos Machado, Fabio Santana Timerman, Ari

6 Scientific Program OCTOBER 22, :00 09:10 Opening Antonio Carlos Lopes, Richard C. Becker, and Renato D. Lopes SESSION I President: Christopher B. Granger 09:10 09:30 Update in Thrombosis and Anticoagulation in Clinical Practice Richard C. Becker 09:40 10:00 Biomarkers of Thrombosis - How and Which one to Use? L. Kristin Newby 10:10 10:30 Anticoagulation in Acute Coronary Syndromes Ari Timerman 10:30 10:50 Coffee Break 10:50 11:10 Triple Therapy - A Management Dilemma Renato D. Lopes 11:20 11:40 Stroke: Should We use Antithrombotics? When and How? Fabio Santana Machado 11:40 12:00 Challenging Cases David Garcia 12:00 14:00 Break SESSION II President: E. Marc Jolicoeur 14:00 15:20 Thrombosis in: Diabetes: L. Kristin Newby Atrial Fibrillation: John H. Alexander Dyslipidemia: Christopher B. Granger Heart Failure/Hypertension: Antonio Carlos Carvalho 15:30 15:50 Management of Bleeding Episodes in Patients receiving Antithrombotic Therapy David Garcia 16:00 16:30 Coffee Break 16:30 17:00 Design Issues and Statistical Considerations around Clinical Research Karen Pieper 17:10 17:40 Challenging Cases Renato D. Lopes / E. Marc Jolicoeur

7 OCTOBER 23, 2009 SESSION III President: Antonio Carlos Lopes 09:00 09:20 VTE prophilaxis in Medical Patients Renato D. Lopes 09:25 09:55 Treatment for VTE Dalton de Alencar F. Chamone 10:00 10:20 Post-thrombotic Syndrome: Epidemiology and Management Richard C. Becker 10:20 10:40 Coffee Break 10:40 11:10 Predicting Cancer Patients at Risk for Venous Thromboembolism: Strategies for Prophylaxis David Garcia 11:15 11:45 Diagnosis and Management of Pulmonary Embolism Antonio Claudio Baruzzi 11:50 12:10 How to Better Interpret the Medical Literature? Karen Pieper 12:15 12:45 Challenging Cases L. Kristin Newby 12:45 14:00 Break SESSION IV President: Christopher B. Granger 14:00 14:20 Globalization of Clinical Research John H. Alexander 14:30 15:00 Anticoagulation in Special Patient Populations E. Marc Jolicoeur 15:10 15:30 Anticoagulation in Intensive Care Units Hélio Penna Guimarães 15:40 16:00 Coffee Break 16:00 16:20 The Latest ACCP Antithrombotic Therapy Guidelines: Important Changes that may Impact Clinical Practice David Garcia 16:30 16:50 Importance of Academic Coordinating Center in Clinical Trials in Thrombosis Allison Handller 17:00 17:30 Challenging Cases Renato D. Lopes / E. Marc Jolicoeur

8 SBCM President and Co-Chairs Antonio Carlos Lopes, MD, PhD, FACP 4 Full Professor of Internal Medicine, Federal University of São Paulo - Paulista School of Medicine 4 Full Professor of Emergency Medicine, Federal University of São Paulo - Paulista School of Medicine 4 PhD - Cardiology, Federal University of São Paulo Paulista School of Medicine 4 President of the Brazilian Society of Internal Medicine 4 President of the Brazilian Clinical Research Institute (BCRI) 4 Fellow of the American College of Physicians Richard C. Becker, MD 4 Professor of Medicine. Divisions of Cardiology and Hematology, Department of Medicine - Duke University Medical Center 4 Director of the Duke Cardiovascular Thrombosis Center Duke Clinical Research Institute (DCRI) 4 Co-director of the Advanced Biomarkers Program Duke Clinical Research Institute (DCRI) Renato Delascio Lopes MD, MHS, PhD 4 Adjunct Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Assistant Director - Clinical Research Fellowship Program Duke Clinical Research Institute (DCRI) 4 Assistant Professor - Department of Internal Medicine Federal University of Sao Paulo - Paulista School of Medicine 4 Executive Director - Brazilian Clinical Research Institute (BCRI)

9 Invited Speakers Christopher B. Granger, MD, FACC 4 Professor of Medicine - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Director, Cardiac Care Unit - Duke University Medical Center 4 Co-Director of Cardiovascular Clinical Trials Duke Clinical Research Institute L. Kristin Newby, MD, MHS 4 Associate Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Co-director of the Cardiac Care Unit Duke University Hospital 4 Co-director of the Advanced Biomarkers Program Duke Clinical Research Institute (DCRI) John Alexander, MD, MHS, FACC 4 Associate Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Director of Early Phase Cardiovascular Research Duke Clinical Research Institute (DCRI) 4 Medical director of Site-Based Clinical Research in Cardiovascular Medicine Duke University Medical Center David Garcia, MD 4 Associate Professor - Department of Internal Medicine Division of Hematology/Oncology University of New Mexico Health Sciences Center 4 Director of Cancer and Thrombosis at the University of New Mexico Cancer Center - Director of the Anticoagulation Management Service at University Hospital

10 Invited Speakers E. Marc Jolicœur, MD, MSc, FRCP 4 Assistant Professor - Division of Cardiology, Department of Medicine - University of Montreal 4 Research Associate, University of Montreal Karen S. Pieper, MS 4 Associate Director for Faculty and Fellow Affairs and Clinical Trials Statistical Operations. Duke Clinical Research Institute (DCRI) Allison Handller RN, BSN, MS 4 Senior Project Leader Cardiovascular Devices Phase III/IV Cardiovascular Mega trials Duke Clinical Rsearch Institute (DCRI) Antonio Carlos Carvalho, MD, PhD, FACC 4 Full Professor of Cardiology, Federal University of São Paulo - Paulista School of Medicine 4 PhD - Cardiology, Federal University of São Paulo - Paulista School of Medicine 4 Scientific Director of the Brazilian Clinical Research Institute (BCRI) 4 Fellow of the American College of Cardiology Dalton de Alencar Fischer Chamone, MD, PhD 4 Full Professor of Hematology and Hemotherapy, São Paulo University Medical School 4 PhD - Hematology and Hemottherapy, University of Louvain, Belgium 4 Associate Professor, São Paulo University Pharmaceutical Sciences School

11 Ari Timerman, MD, PhD 4 Assistant Professor of Cardiology, ABC Foundation School of Medicine, 4 PhD - Cardiology, São Paulo University Medical School 4 Head of the Emergency and Intensive Therapy Division, Dante Pazzanese Institute of Cardiology 4 President of the Cardiopulmonary Resuscitation Division of the Dante Pazzanese Institute of Cardiology 4 Head Professor of the TIC5007, Cardiovascular Emergencies of the Postgraduate Program USP/IDPC Medicine/Technology and Intervention in Cardiology Antonio Claudio Baruzzi, MD, PhD 4 PhD - Cardiology, Institute of the Heart, São Paulo University Medical School 4 Physician of the Intensive Care Center, Albert Einstein Hospital Fabio Santana Machado, MD 4 Medical Coordinator of the Neurosurgical ICU of the Neurosurgery, São Paulo University Medical School 4 Collaborator Professor of the Internal Medicine, São Paulo University Medical School 4 Physician of the Neuro-Intensive Care Unit, Sírio Libanês Hospital Hélio Penna Guimarães, MD 4 Assistant Professor of Internal Medicine, Federal University of São Paulo - Paulista School of Medicine 4 President of the Chapter of Emergency Medicine of the Brazilian Society of Internal Medicine 4 Medical Coordinator, Teaching, Training and Simulation Center, Heart Hospital 4 Financial Director of the Brazilian Clinical Research Institute (BCRI)

12 Organization Support With unrestricted educational grant from Symposium Secretariat Caixa Postal: CEP: São Paulo SP Fax:

OCTOBER 24 and 25, 2014

OCTOBER 24 and 25, 2014 2014 VII INTERNATIONAL SYMPOSIUM OF THROMBOSIS AND ANTICOAGULATION OCTOBER 24 and 25, 2014 HCOR - RUA DESEMBARGADOR ELISEU GUILHERME, 147 PARAÍSO SÃO PAULO SP BRASIL ORGANIZATION: VII INTERNATIONAL SYMPOSIUM

More information

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment

More information

Center of Excellence in Naturopathic Cardiovascular Medicine

Center of Excellence in Naturopathic Cardiovascular Medicine Introducing the Center of Excellence in Naturopathic Cardiovascular Medicine The Heart & Lung Wellness program at Center for Natural Medicine and National College of Natural Medicine WHO WE ARE A Center

More information

Licence for use in the UK is expected before the end of 2011

Licence for use in the UK is expected before the end of 2011 News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms

More information

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

10TH ANNUAL CARDIOVASCULAR DISEASE UPDATE

10TH ANNUAL CARDIOVASCULAR DISEASE UPDATE 10TH ANNUAL CARDIOVASCULAR DISEASE UPDATE CONTINUING MEDICAL EDUCATION WEDNESDAY, OCTOBER 26, 2016 5 6 p.m. Registration and Reception 6 9:20 p.m. Dinner and CME Presentations Landerhaven 6111 Landerhaven

More information

Thrombosis and Hemostasis

Thrombosis and Hemostasis Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism

More information

From Concept to a Published Paper - a guide to excellence in Medical Research.

From Concept to a Published Paper - a guide to excellence in Medical Research. The Course Directors of the New Frontiers in Interventional Cardiology (NFIC), Krakow Cardiovascular Research Institute (KCRI) and Proper Medical Writing (PMW) would like to welcome you to the seminar:

More information

June 2014 CURRICULUM VITAE. Peter E. Friedell, M. D. FACP. 2850 S. Wabash Suite 203. Chicago, Illinois

June 2014 CURRICULUM VITAE. Peter E. Friedell, M. D. FACP. 2850 S. Wabash Suite 203. Chicago, Illinois CURRICULUM VITAE June 2014 Peter E. Friedell, M. D. FACP. 2850 S. Wabash Suite 203 Chicago, Illinois 60616 312-808-0621 office 312-505-5106 cell 815-328-3833 fax pfriedell@gohms.com Personal: Date of Birth

More information

Boehringer Ingelheim Sponsored Satellite Symposia

Boehringer Ingelheim Sponsored Satellite Symposia E X P E R I E N C E D P R O T E C T I O N A satellite symposium held during the International Society on Thrombosis and Haemostasis 2015 Congress Boehringer Ingelheim Sponsored Satellite Symposia International

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

Prior Authorization Guideline

Prior Authorization Guideline Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204

More information

Duke Regional Diabetes Symposium 2012

Duke Regional Diabetes Symposium 2012 Duke Regional Diabetes Symposium 2012 July 13, 2012 8:30 AM 4:30 PM North Carolina Research Campus David H. Murdock Core Laboratory Building First Floor Event Room 150 Research Campus Drive Kannapolis,

More information

Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015

Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT

More information

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

7th annual ConFerenCe location

7th annual ConFerenCe location Sponsors 7th Annual WOMEN and Ischemic Heart Disease Symposium Friday, April 19, 2013 Offered in cooperation with the California Chapter of the American College of Cardiology and WomenHeart: The National

More information

21st Annual OSF Cardiovascular Symposium

21st Annual OSF Cardiovascular Symposium 21st Annual OSF Cardiovascular Symposium new waves in cardiac electrophysiology saturday 18 october 2014 7:00 a.m. 4:00 p.m. embassy suites conference center east peoria, illinois OBJECTIVES Overall Program:

More information

Heart and Vascular Disease in Eastern North Carolina

Heart and Vascular Disease in Eastern North Carolina P Heart and Vascular Disease in Eastern North Carolina Friday, May 20, 2016 East Carolina Heart Institute 115 Heart Drive, Greenville, NC Jointly Provided by East Carolina Heart Institute at ECU,, Office

More information

Bringing Science to Clinical Practice: BEST OF ACC 2015

Bringing Science to Clinical Practice: BEST OF ACC 2015 MAY 29 30, 2015 Eden Roc Miami Beach Bringing Science to Clinical Practice: BEST OF ACC 2015 COURSE DIRECTORS Robert O. Bonow, MD, MACC G. William Dec Jr., MD, FACC COURSE CO-DIRECTORS Akshay S. Desai,

More information

2012 Innovations in Heart Failure and Pulmonary Hypertension

2012 Innovations in Heart Failure and Pulmonary Hypertension ALLEGHENY GENERAL HOSPITAL CARDIOVASCULAR INSTITUTE PRESENTS 2012 Innovations in Heart Failure and Pulmonary Hypertension Friday, September 28, 2012 Marriott Pittsburgh City Center Pittsburgh, Pennsylvania

More information

2014 Emerging Faculty Participants

2014 Emerging Faculty Participants Nazem Akoum, MD, FACC Assistant Professor of Medicine, Clinical Cardiac Electrophysiology EPIC EMR Cardiology Liaison University of Utah Health Sciences nazem.akoum@hsc.utah.edu Areas of Interest: Cardiac

More information

Investor News. PIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016

Investor News. PIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016 Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com American Heart Association (AHA) Scientific Sessions 2016: PIONEER AF-PCI Study

More information

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S. Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint

More information

Gruppo di lavoro: Malattie Tromboemboliche

Gruppo di lavoro: Malattie Tromboemboliche Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant

More information

CVI s 2nd Annual New Paradigms in Arrhythmia Management: The Good, the Bad and the Ugly

CVI s 2nd Annual New Paradigms in Arrhythmia Management: The Good, the Bad and the Ugly Please join us for CVI s 2nd Annual New Paradigms in Arrhythmia Management: The Good, the Bad and the Ugly Sunday, April 21, 2013 Loews Philadelphia Hotel Register today and be entered to win a FREE Apple

More information

Brooklyn Stroke Symposium 2015

Brooklyn Stroke Symposium 2015 Brooklyn Stroke Symposium 2015 May 28, 2015 Brooklyn Public Library Grand Army Plaza Sponsored by Keynote Presentations Sleep Apnea and Stroke: More than a Snore Devin L. Brown, M.D., M.S. Professor of

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012 EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial

More information

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014. Participating Faculty

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014. Participating Faculty CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014 Participating Faculty Hector O. Ventura, MD, FACC Section Head, Cardiomyopathy and

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 SATURDAY, JUNE 25, 2016 Detroit Marriott - Troy, MI AGENDA Time Topic Speaker 7:30 am Registration and Continental Breakfast 8:00 am Opening Remarks/Welcome

More information

EXHIBITOR PROSPECTUS

EXHIBITOR PROSPECTUS American Stroke Association 4 th Annual Connecticut Stroke Conference: TRUMBULL MARRIOTT MERRITT PARKWAY, TRUMBULL, CT EXHIBITOR PROSPECTUS To Whom It May Concern: On behalf of the American Stroke Association,

More information

NOAC in patients with Atrial Fibrillation and Acute Coronary Syndromes

NOAC in patients with Atrial Fibrillation and Acute Coronary Syndromes NOAC in patients with Atrial Fibrillation and Acute Coronary Syndromes Matteo Bertini, MD, PhD Department of Cardiology, Arcispedale S. Anna University of Ferrara Atrial fibrillation and PCI Among ACS

More information

CARDIOLOGY UPDATE 2004

CARDIOLOGY UPDATE 2004 Division of Cardiology Department of Medicine University of California, San Francisco School of Medicine CARDIOLOGY UPDATE 2004 September 30 - October 2, 2004 Carmel Valley Ranch Carmel, California University

More information

23 rd Annual Conference on Cardiovascular Nursing

23 rd Annual Conference on Cardiovascular Nursing 23 rd Annual Conference on Cardiovascular Nursing Thursday, April 11, 2013 7:00 am - 3:45 pm Boston Marriott Newton Newton, MA Keynote Speaker Marvin A. Konstam, MD Chief Physician Executive, The CardioVascular

More information

About the RECORD Clinical Trial Program

About the RECORD Clinical Trial Program About the RECORD Clinical Trial Program Fast facts RECORD was a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism

More information

Learning Objectives Patient Care: Prevention/General Cardiology

Learning Objectives Patient Care: Prevention/General Cardiology Rotation: Director: Faculty: Preventive /General Cardiology Emily G. Kurtz, M.D./Waleed Irani, M.D. Prevention: Jeff Boord, M.D., Sergio Fazio, M.D., Emily G. Kurtz, M.D., MacRae Linton, M.D., David Maron,

More information

HHT Center of Excellence The University of Texas, Southwestern. Dallas, Texas

HHT Center of Excellence The University of Texas, Southwestern. Dallas, Texas HHTCenterofExcellence TheUniversityofTexas,Southwestern Dallas,Texas Medical Director, Pulmonary Consultant Daniel Goodenberger, M.D. Professor of Medicine Phone (214)857-0409 FAX (214)857-1457 e-mail:

More information

Cardiac Care Associates 2014 Annual Meeting

Cardiac Care Associates 2014 Annual Meeting Cardiac Care Associates 2014 Annual Meeting March 7, 2014 Villa Christina Restaurant at Perimeter Co-provided by the American College of Cardiology Foundation and The Georgia Chapter of the American College

More information

CHAPTER. 9th Annual Meeting October 12, 2013 8:00 am - 4:30 pm University of Kentucky Albert B. Chandler Hospital Auditorium Lexington, Kentucky

CHAPTER. 9th Annual Meeting October 12, 2013 8:00 am - 4:30 pm University of Kentucky Albert B. Chandler Hospital Auditorium Lexington, Kentucky Kentucky CHAPTER 9th Annual Meeting October 12, 2013 8:00 am - 4:30 pm Albert B. Chandler Hospital Auditorium Lexington, Kentucky Coronary Pathologies: Atherosclerosis and Beyond Please join your fellow

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening

More information

EXHIBITOR PROSPECTUS

EXHIBITOR PROSPECTUS American Heart Association Newton Marriott, Newton, MA EXHIBITOR PROSPECTUS To Whom It May Concern: On behalf of the American Heart Association and the members of the Boston Cardiovascular Nursing committee,

More information

Heart Failure: From Prevention to Intervention

Heart Failure: From Prevention to Intervention Sharp HealthCare Presents Heart Failure: From Prevention to Intervention Saturday, May 16, 2015 DoubleTree by Hilton Hotel San Diego - Mission Valley San Diego, Calif. As medical professionals, we know

More information

Cardiac Rehabilitation: Strategies Approaching 2020

Cardiac Rehabilitation: Strategies Approaching 2020 ACC Banff 2015 Cardiac Rehabilitation: Strategies Approaching 2020 James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Libin Cardiovascular

More information

FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M.

FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M. CEDARS-SINAI HYPERTENSION CENTER 2016 Clinical Highlights Symposium FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M. CONFERENCE LOCATION Harvey Morse Conference Center 8701 Gracie Allen Drive Plaza Level,

More information

F I V E - P H A S E P R O G R A M O V E R V I E W, P A T I E N T S U R V E Y, M O N I T O R I N G T O O L S, A N D P H Y S I C I A N P E R F O R M A N C E EVALUATION: FACULTY AND LOCATIONS Improving Risk

More information

Patients with Atrial Fibrillation and PCI or ACS Need Triple Therapy - Practical Guidance

Patients with Atrial Fibrillation and PCI or ACS Need Triple Therapy - Practical Guidance Patients with Atrial Fibrillation and PCI or ACS Need Triple Therapy - Practical Guidance Christopher P. Cannon, M.D. Executive Director, Cardiometabolic Trials, Harvard Clinical Research Institute Cardiovascular

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Presented by Susan Haviland, BSN RN Senior Consult, Santa Rosa Consulting Meaningful Use Quality Measures Centers for Medicare and Medicaid Services

More information

Minimally Invasive Cardiac Surgery

Minimally Invasive Cardiac Surgery 3rd Annual Bakken Symposium Minimally Invasive Cardiac Surgery December 7 & 8, 2009 Mayo Auditorium, COURSE DIRECTORS: Kenneth K. Liao, MD, PhD James D. St. Louis, MD Presented by Department of Surgery

More information

Cardio Renal Connections Inaugural Conference April 16-17, 2016 San Antonio, Texas

Cardio Renal Connections Inaugural Conference April 16-17, 2016 San Antonio, Texas Registration Form Cardio Renal Connections Inaugural Conference April 16-17, 2016 San Antonio, Texas First and Last Name: Credentials: r MD r DO r Fellow r Resident r Student r Nurse r Other Institution:

More information

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL) PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)

More information

Coronary CTA in the Emergency Department A Hands-on Workshop

Coronary CTA in the Emergency Department A Hands-on Workshop Coronary CTA in the Emergency Department A Hands-on Workshop November 7-8, 2009 Eden Roc Hotel Miami Beach, Florida Symposium Director Coronary CTA in the Emergency Department: A Hands-on Workshop Target

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with

More information

CURRICULUM VITAE. DRAGOS VINEREANU, MD, PhD, EC, FESC

CURRICULUM VITAE. DRAGOS VINEREANU, MD, PhD, EC, FESC CURRICULUM VITAE DRAGOS VINEREANU, MD, PhD, EC, FESC PERSONAL DATA: Date and place of birth: 14th July 1966, Pitesti, Romania Citizenship: Romanian Permanent address: Home: Aleea Politehnicii, Nr 10, Bl

More information

AMERICAN COLLEGE of CARDIOLOGY

AMERICAN COLLEGE of CARDIOLOGY AMERICAN COLLEGE of CARDIOLOGY CARDIAC CARE ASSOCIATE MEMBERSHIP APPLICATION Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant Clinical Pharmacist Improve Patient Care,

More information

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Jonathan Sykes MD, CMIO Jacalyn Liebowitz RN, MBA,NEA-BCFACHE VP Care Continuum Allegiance Health - Jackson, MI DISCLAIMER:

More information

FACULTY OF ALLIED HEALTH SCIENCES

FACULTY OF ALLIED HEALTH SCIENCES FACULTY OF ALLIED HEALTH SCIENCES 102 Naresuan University FACULTY OF ALLIED HEALTH SCIENCES has focused on providing strong professional programs, including Medical established as one of the leading institutes

More information

Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant. Cardiac Care Associate Membership application

Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant. Cardiac Care Associate Membership application American College of Cardiology Cardiac Care Associate Membership application Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant Improve Patient Care, Increase Facility Performance,

More information

2016 Cardiovascular Update

2016 Cardiovascular Update 2016 Cardiovascular Update March 18, 2016 Villa Christina Restaurant at Perimeter Jointly Provided by the American College of Cardiology Foundation and The Georgia Chapter of the American College of Cardiology

More information

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart

More information

SECTION I: Request. SECTION II: Need. Program Description

SECTION I: Request. SECTION II: Need. Program Description SECTION I: Request This is a formal request for the Utah CARMA Center to be formally recognized by the University of Utah as a large, collaborative medical and academic center whose focus is on comprehensive

More information

CURRENT ADVANCES IN CARDIOVASCULAR CARE 2016

CURRENT ADVANCES IN CARDIOVASCULAR CARE 2016 CURRENT ADVANCES IN CARDIOVASCULAR CARE 2016 A C M E / C N E - C E R T I F I E D C O U R S E REGISTRATION 7:00 7:45 am SCIENTIFIC PROGRAM 7:45 am 4:15 pm The Wyndham Garden Exton Valley Forge 815 North

More information

The 16th Annual Meeting

The 16th Annual Meeting The 16th Annual Meeting of the INDIANA Chapter of the American College of Cardiology The Indianapolis Marriott Downtown Indianapolis, Indiana Saturday, October 27, 2012 Special Session for Fellows-in-Training

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

Jeffrey R. Gladden, M.D., F.A.C.C. Dr. Benedict Maniscalco

Jeffrey R. Gladden, M.D., F.A.C.C. Dr. Benedict Maniscalco Jeffrey R. Gladden, M.D., F.A.C.C. Dr. Jeffrey Gladden has been practicing in North Texas since 1988 and founded Advanced Heart Care in 1997. Dr. Gladden also co-founded the Heart Hospital at Baylor Plano,

More information

May 20, 2016. May 21, 2016. The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium. Comprehensive Stroke Symposium

May 20, 2016. May 21, 2016. The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium. Comprehensive Stroke Symposium The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium May 20, 2016 Comprehensive Stroke Symposium May 21, 2016 Emergency Neurological Life Support Course and Certification The Richmond Marriott

More information

Program All meetings are on the Convention Level unless otherwise noted.

Program All meetings are on the Convention Level unless otherwise noted. 1 Program All meetings are on the Convention Level unless otherwise noted. Wednesday, June 24, 2015 Day 1 Begin/End Time Function Meeting Room Noon 5:00 pm Attendee Arrival Registration Badge pick-up Events

More information

friday 30 may 2008 brussels belgium Sheraton Brussels Hotel Place Rogier 3 Rogierplein B- 1210 Brussels

friday 30 may 2008 brussels belgium Sheraton Brussels Hotel Place Rogier 3 Rogierplein B- 1210 Brussels friday 30 may 2008 brussels belgium 1 ST Belgian Congress on Acute Cardiac Care Sheraton Brussels Hotel Place Rogier 3 Rogierplein B- 1210 Brussels Dear Colleagues, On behalf of the Belgian Interdisciplinary

More information

San Antonio Heart Failure Symposium 2015

San Antonio Heart Failure Symposium 2015 San Antonio Heart Failure Symposium 2015 Continuing Medical Education Saturday, February 28, 2015 Expert Faculty, 8 Hours CME, 8 Hours CEU Comprehensive review and latest updates in: - Heart failure -

More information

Backgrounder. Current anticoagulant therapies

Backgrounder. Current anticoagulant therapies Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events

More information

A C C O M M O D A T I O N S D I R E C T I O N S. Exhibitor tables will be accessible at 7:30 a.m.

A C C O M M O D A T I O N S D I R E C T I O N S. Exhibitor tables will be accessible at 7:30 a.m. R E g I S T R AT I O N I N F O R M AT I O N There is a $55 fee for Christiana Care Health System (CCHS) employees ($75 day of registration, if seating permits), $75 fee for non-cchs employees ($95 day

More information

International Conference and Exhibition on. Matt McCarty CEO, Genotox Laboratories USA. Mark Versavel President vzenium LLC, USA.

International Conference and Exhibition on. Matt McCarty CEO, Genotox Laboratories USA. Mark Versavel President vzenium LLC, USA. International Conference and Exhibition on Pain Medicine Renowned Speakers Chicago, USA June 08-10, 2015 Gabor Racz Professor and Co-Director Pain Program, USA Matt McCarty CEO, Genotox Laboratories USA

More information

CURRICULUM VITAE. Jane/John G. Doe, M.D., Ph.D. Associate Professor of Medicine (and include Administrative Title) Division of Cardiovascular Medicine

CURRICULUM VITAE. Jane/John G. Doe, M.D., Ph.D. Associate Professor of Medicine (and include Administrative Title) Division of Cardiovascular Medicine Date of Document [Listing of all dates should be with oldest (first) to most recent (last)] CURRICULUM VITAE Jane/John G. Doe, M.D., Ph.D. Associate Professor of Medicine (and include Administrative Title)

More information

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Updates to the Alberta Drug Benefit List. Effective January 1, 2016 Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

-more- For immediate release: November 1, 2012

-more- For immediate release: November 1, 2012 For immediate release: November 1, 2012 Portola Pharmaceuticals Media Contact: Paul Laland, WCG for Portola plaland@wcgworld.com 415-946-1071 Bristol-Myers Squibb Media Contact: Laura Hortas, 609-252-4587

More information

24 th Annual Conference on Cardiovascular Nursing

24 th Annual Conference on Cardiovascular Nursing 24 th Annual Conference on Cardiovascular Nursing Presented by the American Heart Association s Boston Cardiovascular Nursing Committee Wednesday, April 2, 2014 7:00 am - 3:45 pm Boston Marriott Newton,

More information

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,

More information

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary

More information

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin. To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation

More information

STEMI & CARDIAC ARREST

STEMI & CARDIAC ARREST STEMI & CARDIAC ARREST CONFERENCE 2015 May 6, 2015 Registration 7:30 am Program 7:50 am 4:00 pm East Carolina Heart Institute at East Carolina University Greenville, NC Jointly Provided by East Carolina

More information

AnMed Health Disparities Dashboard

AnMed Health Disparities Dashboard AnMed Health Quick Facts 588 Bed Acute Care System Level II Trauma Center Emergency Department visits: 112,329 Admissions: 23,489 Active Medical Staff: 455 Employees: 3,511 Source : CY2013 Setting the

More information

Deep Vein Thrombosis

Deep Vein Thrombosis Deep Vein Thrombosis Evaluation and Management Considerations Mark R. Gazall, D.O. Maryland Vascular Specialists Professor of Surgery Ohio University, Athens Ohio Deep Vein Thrombosis A Treatment Option

More information

Objectives. Patient Background. Transitioning a Patient To & From a New Oral Anticoagulant

Objectives. Patient Background. Transitioning a Patient To & From a New Oral Anticoagulant Objectives Transitioning a Patient To & From a New Oral Anticoagulant How to switch from warfarin to rivaroxaban Discuss the Medicare donut hole How to switch from rivaroxaban to warfarin Home INR monitoring

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications

More information

Advances in Pulmonary Hypertension

Advances in Pulmonary Hypertension Advances in Pulmonary Hypertension August 5, 2016 Gallery at GreenRiver Lavin Family Pavilion - 18th Floor Chicago, Illinois General Information Learning Objectives At the conclusion of this activity,

More information